UmanDiagnostics AB
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
UmanDiagnostics AB - overview
Established
2006
Location
Umea, -, Sweden
Primary Industry
Medical Devices & Equipment
About
UmanDiagnostics AB develops advanced diagnostic tools for early detection of neurological diseases, focusing on Neurofilament light (NF-L) protein quantification through innovative assays and monoclonal antibodies for precise health assessments. UmanDiagnostics AB, founded in 2006 in Umea, Sweden, specializes in diagnostics for neurological disorders. The company was acquired by Quanterix Corporation in June 2019 for USD 22. 50 mn.
The founder's history is not available; however, the company has secured one deal since its inception. UmanDiagnostics specializes in creating diagnostic assays that facilitate early detection of neurological diseases. Their key products include the NF-light™ Serum ELISA assay and the NF-light™ ELISA for cerebrospinal fluid samples, enabling accurate measurement of NF-L levels, indicative of neuronal damage. These products cater to research institutions, clinical labs, and healthcare facilities focusing on conditions like Multiple Sclerosis and Amyotrophic Lateral Sclerosis.
Additionally, the company offers anti-NF-light monoclonal antibodies, expanding their portfolio to meet diverse client needs across Europe, North America, and Asia. In 2023, UmanDiagnostics generated revenue of USD 5,027,790. 50 and an EBITDA of USD 3,461,268. 50, primarily through direct sales of diagnostic assays and antibodies to healthcare providers and research institutions.
UmanDiagnostics plans to enhance its product offerings with new diagnostic tools aimed at expanding their portfolio by 2025. The company targets growth in emerging markets in Asia and Latin America, aiming for increased market penetration by the end of 2024. The funding received from the acquisition by Quanterix Corporation will support these expansion efforts and product development initiatives.
Current Investors
Quanterix Corporation
Primary Industry
Medical Devices & Equipment
Sub Industries
Monitoring Equipment, Diagnostic Equipment
Website
www.umandiagnostics.com
Company Stage
Add-on
Total Amount Raised
Subscriber access only
UmanDiagnostics AB - timeline of key events
UmanDiagnostics AB - financials
| Fiscal Year Ended | Dec 31, 2011 | Dec 31, 2012 | Dec 31, 2013 | Dec 31, 2014 | Dec 31, 2015 | Dec 31, 2016 | Dec 31, 2017 | Dec 31, 2018 | Dec 31, 2019 | Dec 31, 2020 | Dec 31, 2021 | Dec 31, 2022 | Dec 31, 2023 | Dec 31, 2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue (USD) | 2,251,794 | 2,447,000 | 2,309,580 | 3,117,922 | 4,376,780 | 7,189,770 | 16,850,606 | 21,085,173 | 29,032,654 | 18,808,904 | 36,174,794 | - | - | - |
| % Revenue Growth (YoY) | - | 8.7% | (5.6%) | 35.0% | 40.4% | 64.3% | 134.4% | 25.1% | 37.7% | (35.2%) | 92.3% | - | - | - |
| EBITDA (USD) | 591,296 | 835,140 | 150,330 | 775,193 | 1,431,555 | 3,069,812 | 10,472,097 | 13,488,606 | 12,905,257 | 5,487,291 | 21,418,442 | - | - | - |
| Operating Income (USD) | (139,392) | 334,687 | (351,416) | 428,076 | 1,394,685 | 3,017,605 | 10,380,444 | 13,351,091 | 12,777,074 | 5,071,031 | 20,804,728 | - | - | - |
| Operating Margin | (6.2%) | 13.7% | (15.2%) | 13.7% | 31.9% | 42.0% | 61.6% | 63.3% | 44.0% | 27.0% | 57.5% | - | - | - |
| % EBITDA Margin | 26.3% | 34.1% | 6.5% | 24.9% | 32.7% | 42.7% | 62.1% | 64.0% | 44.5% | 29.2% | 59.2% | - | - | - |
| NET Income (USD) | (198,063) | 304,649 | (354,530) | 418,465 | 865,071 | 1,746,855 | 8,884,279 | 10,525,578 | 10,220,137 | 3,968,515 | 16,533,094 | - | - | - |
| % Net Margin | (8.8%) | 12.4% | (15.4%) | 13.4% | 19.8% | 24.3% | 52.7% | 49.9% | 35.2% | 21.1% | 45.7% | - | - | - |
UmanDiagnostics AB - employee data
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.